Research programme: antiviral therapeutics - Chimerix

Drug Profile

Research programme: antiviral therapeutics - Chimerix

Alternative Names: CMX 014; CMX 16669; CMX 521; CMX669

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Chimerix
  • Class Drug conjugates; Hypoxanthines
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Norovirus infections; Viral infections
  • Research Influenza virus infections
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 07 Nov 2016 Preclinical trials in Norovirus infections in USA
  • 07 Nov 2016 Chimerix intends to file an IND application with the US FDA for CMX 521 for Norovirus infections, in 2017
  • 20 Oct 2014 Discontinued - Preclinical for Hepatitis B and Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top